Aquaculture (Aquafarming) market is the largest segment driving the growth of Fish Skin Disease Market.
SWOT Analysis
Strengths: Increasing adoption of probiotics and organic acids reduces dependency on antibiotics.
Weaknesses: High costs associated with R&D of alternative therapies. Lack of awareness in some regions.
Opportunities: Growing aquaculture industry drives demand. Scope for development of new drugs and vaccines.
Threats: Threat from other diseases in aquaculture like Viral Nervous Necrosis. Stringent regulations associated with antibiotics and vaccine approvals.
Key Takeaways
The Global Fish Skin Disease Market Size is expected to witness high growth, exhibiting CAGR of 7.1% over the forecast period, 2023 to 2030, due to increasing adoption of sustainable aquaculture practices.
Regional analysis:
Asia Pacific is expected to dominate the fish skin disease market over the forecast period. This is attributed to rising fish farming in China, India, and other Southeast Asian countries. Large freshwater farms are prone to skin infections in carp, tilapia and catfish species. North America and Europe are other major markets driven by salmon farming.
Key players:
Key players operating in the fish skin disease market are Zoetis Inc., Elanco Animal Health, MSD Animal Health, Benchmark Holdings, Phibro Animal Health Corporation, Intervet Inc., Norvartis, Merck Animal Health, Novartis AG, Pharmaq AS, AquaBounty Technologies, Alltech, Skretting, Nutreco, Biomin. Leading players are focusing on tackling antibiotic resistance through development of novel alternative therapeutics and vaccines.
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian